Pilocarpine Therapy for Sjögren's Syndrome

Mechanism of Action and Efficacy

Pilocarpine is a cholinergic agonist that binds to muscarinic receptors, stimulating secretion of salivary and sweat glands, and improving tear production in patients with Sjögren's syndrome 3, 4
The medication shows greater improvement in dry mouth symptoms than dry eye symptoms at the standard 20 mg/day dosage, as reported by the American College of Rheumatology 1, 2
Pilocarpine increases salivary flow 2-3 fold compared to placebo, with effects maintained throughout 12 weeks of treatment in patients with Sjögren's syndrome 1, 2

The most common side effect is excessive sweating, occurring in over 40% of patients with Sjögren's syndrome taking pilocarpine 3
Approximately 2% of patients discontinue treatment due to side effects, primarily excessive sweating, as noted in studies published in Ophthalmology 5
Cevimeline, another muscarinic agonist, may have fewer adverse systemic side effects than pilocarpine but is not as widely available worldwide, according to the American Academy of Ophthalmology 5, 6

For mild glandular dysfunction, a first-line approach includes non-pharmacological stimulation with sugar-free acidic candies, lozenges, or chewing gum, as recommended by the European League Against Rheumatism 1, 2
For moderate glandular dysfunction or those who fail non-pharmacological approaches, initiate pilocarpine at 5 mg four times daily, as suggested by the American College of Rheumatology 1, 2
For severe dry eye with no salivary output, consider saliva substitution in addition to pilocarpine, as recommended by the Sjögren's Syndrome Foundation 1, 2